Evaluation in vitro and in animals of a new 11C-labeled PET radioligand for metabotropic glutamate receptors 1 in brain
- 501 Downloads
Two allosteric modulators of the group I metabotropic glutamate receptors (mGluR1 and mGluR5) were evaluated as positron emission tomography (PET) radioligands for mGluR1.
LY2428703, a full mGluR1 antagonist (IC50 8.9 nM) and partial mGluR5 antagonist (IC50 118 nM), and LSN2606428, a full mGluR1 and mGluR5 antagonist (IC50 35.3 nM and 10.2 nM, respectively) were successfully labeled with 11C and evaluated as radioligands for mGluR1. The pharmacology of LY2428703 was comprehensively assessed in vitro and in vivo, and its biodistribution was investigated by liquid chromatography-mass spectrometry/mass spectrometry, and by PET imaging in the rat. In contrast, LSN2606428 was only evaluated in vitro; further evaluation was stopped due to its unfavorable pharmacological properties and binding affinity.
11C-LY2428703 showed promising characteristics, including: (1) high potency for binding to human mGluR1 (IC50 8.9 nM) with no significant affinity for other human mGlu receptors (mGluR2 through mGluR8); (2) binding to brain displaceable by administration of an mGluR1 antagonist; (3) only one major radiometabolite in both plasma and brain, with a negligible brain concentration (with 3.5 % of the total radioactivity in cerebellum) and no receptor affinity; (4) a large specific and displaceable signal in the mGluR1-rich cerebellum with no significant in vivo affinity for mGluR5, as shown by PET studies in rats; and (5) lack of substrate behavior for efflux transporters at the blood–brain barrier, as shown by PET studies conducted in wild-type and knockout mice.
11C-LY2428703, a new PET radioligand for mGluR1 quantification, displayed promising characteristics both in vitro and in vivo in rodents.
KeywordsmGlu1 receptors PET Brain
The authors are grateful to the NIH Clinical PET Center (Chief, Dr. P. Herscovitch) for cyclotron production of carbon-11. Ioline Henter provided excellent editorial assistance.
This work was supported in part by the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH).
- 1.Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R. Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol. 2003;14:257–77.PubMedCrossRefGoogle Scholar
- 7.Simeon FG, Brown AK, Zoghbi SS, Patterson VM, Innis RB, Pike VW. Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. J Med Chem. 2007;50:3256–66.PubMedCrossRefGoogle Scholar
- 11.Fujinaga M, Yamasaki T, Kawamura K, Kumata K, Hatori A, Yui J, et al. Synthesis and evaluation of 6-[1-(2-[(18)F]fluoro-3-pyridyl)-5-methyl-1H-1,2,3-triazol-4-yl]quinoline for positron emission tomography imaging of the metabotropic glutamate receptor type 1 in brain. Bioorg Med Chem. 2011;19:102–10.PubMedCrossRefGoogle Scholar
- 12.Yamasaki T, Fujinaga M, Yoshida Y, Kumata K, Yui JJ, Kawamura K, et al. Radiosynthesis and preliminary evaluation of 4-[(18)F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg Med Chem Lett. 2011;21:2998–3001.PubMedCrossRefGoogle Scholar
- 15.Tsui HT, Gillard SE, Argilli E, Zia-Ebrahimi M, Vannieuwenhze MS, Wheeler WJ, et al. (3H)-LY456066, a potent subtype selective radioligand for metabotropic glutamate receptor subtype 1. Society for Neuroscience Meeting. 2002; Abstract no. 247.3.Google Scholar
- 16.Raub TJ, Lutzke BS, Andrus PK, Sawada GA, Staton BA. Early preclinical evaluation of brain exposure in support of hit identification and lead optimization. In: Borchardt RT, Middaugh CR, editors. Optimizing the “drug-like” properties of leads in drug discovery. Biotechnology: Pharmaceutical Aspects Series. Berlin: Springer; 2006. p. 355–410.Google Scholar